# BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

> **NCT03931642** · PHASE2 · COMPLETED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 41 (actual)

## Conditions studied

- Richter Syndrome

## Interventions

- **DRUG:** RCHOP
- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT03931642
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-05
- **Primary completion:** 2021-10-01
- **Final completion:** 2022-10-21
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03931642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03931642, "BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03931642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*